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HPV Vaccine Acceptance among Latina Mothers
by HPV Status
Maureen Sanderson, Ph.D.,1 Ann L. Coker, Ph.D.,2 Katherine S. Eggleston, M.P.H.,2
Maria E. Fernandez, Ph.D.,3 Concepcion D. Arrastia, M.D.,4 and Mary K. Fadden, M.P.H.1
Abstract
Objective: We investigated whether Latina mothers who were and were not human papillomavirus (HPV)
positive differed in their knowledge and acceptance of the HPV vaccine for their children.
Methods: We conducted a cross–sectional survey among women aged 18–64 years between April 2007 and April
2008. Data collectors conducted in-person interviews in community clinics with 215 HPV-negative women and
190 HPV-positive women (with respective response rates of 64% and 84%). Most (83%) HPV-positive women
were recruited at dysplasia clinics. Although no HPV-negative women were recruited at dysplasia clinics, they
were recruited at other low-income public and private clinics.
Results: After adjustment for age, marital status, and health insurance, women who were HPV positive were
more likely than HPV-negative women to have heard about the HPV vaccine, to indicate they would have their
daughters and sons vaccinated against cervical cancer even if they had to pay themselves, and to be in favor of
the proposed Texas law requiring girls to receive the HPV vaccine before entry into sixth grade but less likely to
be in favor of girls receiving the vaccine at age 13.
Conclusions: Our findings indicate that >90% of Latinas living on the Texas-Mexico border find the HPV vaccine
acceptable for their own daughters and sons.
Introduction
The finding that human papillomavirus (HPV) is anecessary cause of cervical cancer has led to the devel-
opment of vaccines against HPV types 16 and 18, which have
been found in 70% of cervical cancers.1 A phase II clinical trial
of the monovalent HPV type 16 vaccine showed 100% efficacy
against cervical intraepithelial neoplasia (CIN) in low-risk
women over an 18-month period.2 Preliminary analyses from
a recent phase III clinical trial reported the bivalent HPV types
16=18 vaccine was 90.4% efficacious against CIN2þ in high-
risk women over a 14.8-month period.3 In June 2006, the
quadrivalent HPV types 6=11=16=18 vaccine was approved
by the Food and Drug Administration (FDA) for prophylactic
use by girls and women aged 9–26 years in the United States.
If a majority of young women receive the recently available
HPV vaccine, CIN and cervical cancer incidence and mortality
rates should dramatically decline.
The development of the vaccine is especially important in
such areas as the Lower Rio Grande Valley (LRGV) of Texas,
the four southernmost counties on the Mexico border, which
has much higher cervical cancer incidence and mortality rates
than the rest of the United States.4,5 From 2001 through 2005,
the average annual age-adjusted cervical cancer incidence rate
for the LRGV among Latinas (14.3 of 100,000), the predomi-
nant ethnic group, was higher than the rate among Latinas in
the United States (13.2 of 100,000). The difference in mortality
rates between the LRGV and the United States was even more
pronounced (LRGV 4.9 of 100,000 vs. United States 3.2 of
100,000). A possible explanation for the higher rates among
Latinas is their higher prevalence of correlates of HPV posi-
tivity relative to women of other ethnicities. Giuliano et al.6
conducted a study of Mexican American women in Tucson
and found the highest prevalence of HPV in women who had
more than one lifetime sexual partner, women  25 years of
age, single women, women born in Mexico, and women who
did not use oral contraceptives.
In its current formulation, the HPV vaccine’s effectiveness
depends greatly on uptake of the vaccine by parents for their
children. Two large quantitative studies of HPV vaccine ac-
ceptability showed greater acceptance among parents with a
history of genital warts7 or HPV infection8 themselves, but
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two small qualitative studies did not find greater acceptance
among parents with a history of sexually transmitted infec-
tions (STI).9,10 Two large8,11 and one small study9 reported
no association between history of abnormal Pap tests and
greater HPV vaccine acceptability. The question remains
whether a woman’s diagnosis with HPV or an abnormal Pap
test is associated with her decision on HPV vaccine accept-
ability. The purpose of the present study was to determine
if there are differences in knowledge and acceptability of the
HPV vaccine for their children between HPV-positive and
HPV-negative Latinas living on the Texas-Mexico border.
Materials and Methods
As part of a larger clinic-based cohort study to investigate
knowledge gaps and information needs of women who are
HPV positive, we conducted in-person interviews in two
Texas-Mexico border counties from April 2007 through April
2008. Two groups of Latina women aged 18–64 years were
recruited: women who were HPV positive (n¼ 190), and
women who were HPV negative (n¼ 215). Response rates
were 84% and 64%, respectively. Clinic gynecologists iden-
tified HPV-positive women shortly after an HPV diagno-
sis and prior to treatment. The majority of HPV-positive
subjects were recruited from the dysplasia clinic that pro-
vided diagnosis and treatment for women participating in
the Texas Breast and Cervical Cancer Screening Program.
HPV-negative women were recruited in the waiting rooms of
community health centers, Planned Parenthood clinics, and
private clinics. HPV negative women with an abnormal Pap
test in the past 5 years or history of treatment for an abnormal
Pap test were excluded.
Trained data collectors asked women about their knowl-
edge of HPV and the HPV vaccine, their concerns about
the HPV vaccine, and their intention to have their children
vaccinated against HPV. Initially, women were asked the
closed-ended questions: Have you ever heard of human
papillomavirus, sometimes referred to as HPV? and Have you
ever heard of a vaccine for HPV? All women, regardless of
their HPV knowledge, were then provided with the follow-
ing information about the HPV vaccine: A vaccine for certain
types of HPV is available. Right now, the vaccine is only for
girls and women between the ages of 9 and 26 who do not
already have HPV. The vaccine will help to stop people from
getting HPV, genital warts, and cervical cancer but will not
treat or cure people who already have HPV. HPV is a sexually
transmitted infection. The vaccine is given in a series of 3
shots, and may cost between $30 and $150 per shot.
We recognize that women who already have HPV can get
vaccinated, as there are no requirements for HPV testing prior
to vaccination; however, we found in focus groups that women
were confused about the purpose of vaccination without
the qualifier that the vaccine is meant for girls and women
who do not already have HPV. An open-ended question on
HPV vaccine concerns was used: What concerns, if any, do
you have about the current HPV vaccine, called Gardasil
[Merck, Rahway, NJ]? You may have seen television com-
mercials called ‘‘One less’’ or ‘‘Tell someone’’ about the HPV
vaccine. A series of closed-ended questions were then asked
about HPV vaccine acceptability: If you are a parent or be-
came a parent, do you think that you would have your
teenage daughter get the HPV vaccine to prevent cervical
cancer? If you are a parent or became a parent, do you think
that you would have your teenage son get the HPV vaccine to
prevent cervical cancer in a partner? If you are a parent or
became a parent, do you think you would have your teenage
daughter get the HPV vaccine even if you had to pay for the
vaccine yourself because your insurance or other public funds
did not cover the cost? Are you in favor of Texas state law
requiring all girls get the vaccine before entry into sixth grade?
and At what age do you think girls should be vaccinated
against HPV? The questions about prevention of cervical
cancer were also asked about genital warts; however, the re-
sults were identical and are not presented. Two additional
closed-ended questions were asked of the subset of women
who had daughters in the 9–18 age range about HPV vaccine
behavioral intentions and knowledge: How likely are you to
have your daughter get the vaccine? and Do you know where
you could go to get the vaccine?
We used stratified analysis to assess the associations be-
tween HPV status and HPV vaccine characteristics. Although
this was a cross-sectional survey, we calculated relative risks
(RR) using stratified analysis in order to compare two co-
horts of women. Because 100% of HPV-positive women re-
ported that they were likely to have their daughter vaccinated
(among women with daughters aged 9–18), we were unable
to calculate RRs. In order to calculate RRs, we added 0.5 to a
zero cell for this variable. We examined confounding by age,
birthplace, language used for the interview, educational level,
marital status, health insurance, whether they had children,
time between vaccine approval and interview, and recruit-
ment site.
Results
Table 1 shows the demographic characteristics of HPV-
positive and HPV-negative women. HPV-positive women
were more likely than HPV-negative women to be younger,
to be unmarried, to have Medicaid, and to have been inter-
viewed more months after the vaccine was approved but less
likely to be recruited from a private clinic. Subsequent ana-
lyses are adjusted for age, marital status, and health insur-
ance. Additional adjustment for time since vaccine approval
and recruitment site did not materially change the RRs.
Table 2 presents HPV vaccine knowledge and acceptance
among HPV-positive and HPV-negative women and RRs for
these HPV vaccine characteristics by HPV status. A greater
percentage of HPV-positive women than HPV-negative wo-
men had heard of HPV (positive, 67%, vs. negative, 61%) and
of the HPV vaccine (positive, 73%, vs. negative, 58%); how-
ever, only the difference in knowledge of the HPV vaccine
was significantly different (RR 1.45, 95% confidence interval
[CI] 1.09–1.93). A total of 71% of HPV-positive and 77% of
HPV-negative women reported they had no concerns about
the HPV vaccine. Of those women reporting a concern, the
most frequent concern among both groups was long-term side
effects, and the second most frequent concern differed by
HPV status (positive, effectiveness, vs. negative, short-term
side effects).
Nearly all HPV-positive women stated they would have
their daughters and sons vaccinated against HPV to prevent
cervical cancer, in comparison with a slightly lower percent-
age of HPV-negative women (Table 2). The majority of women
in both groups were in favor of the Texas law mandating the
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Table 1. Demographic Characteristics of Study Participants
HPV positive n¼ 190 HPV negative n¼ 215
Characteristic n (%) n (%) Chi-square p value
Age, years
18–24 61 (32.1) 53 (24.6) 17.77 0.0005
25–34 82 (43.2) 74 (34.4)
35–44 37 (19.5) 50 (23.3)
45–64 10 (5.3) 38 (17.7)
Birthplace
United States 74 (39.0) 88 (40.9) 0.17 0.68
Mexico 116 (61.0) 127 (59.1)
Amount of time in United States, years
<2 6 (5.2) 17 (13.4) 15.76 0.008
2–5 23 (19.8) 25 (19.7)
6–10 28 (24.1) 30 (23.6)
11–15 27 (23.3) 17 (13.4)
16–20 21 (18.1) 12 (9.5)
>20 11 (9.5) 26 (20.5)
Language used to complete interview
English 85 (44.7) 79 (36.7) 2.67 0.10
Spanish 105 (55.34) 136 (63.3)
Marital status
Unmarried 67 (35.3) 59 (27.6) 11.25 0.004
Married=living with partner 88 (46.3) 133 (62.1)
Divorced=widowed=separated 35 (18.4) 22 (10.3)
Missing 0 1
Educational level
Less than high school 91 (47.9) 110 (51.4) 0.67 0.72
High school graduate 59 (31.1) 59 (27.6)
More than high school 40 (21.0) 45 (21.0)
Missing 0 1
Health insurance
Private insurance 6 (3.3) 36 (16.9) 46.85 <0.0001
Medicaid 81 (44.5) 35 (16.4)
Self-pay 95 (52.2) 142 (66.7)
Missing 8 2
Have children
No 43 (22.6) 37 (17.2) 1.87 0.17
Yes 147 (77.4) 178 (82.8)
Gender and age of children (years)
Female
9–18 41 (28.5) 63 (35.4) 24.01 0.0002
<9 45 (31.3) 29 (16.3)
>18 3 (2.1) 25 (14.0)
Male
9–18 22 (15.3) 31 (17.4)
<9 29 (20.1) 25 (14.0)
>18 4 (2.8) 5 (2.8)
Missing 3 0
Time between vaccine approval and
interview, months
10–12 34 (17.9) 33 (15.4) 143.28 <0.0001
13–15 66 (34.7) 182 (84.7)
>15 90 (47.4) 0 (0.0)
Recruitment site
Dysplasia clinic 157 (82.6) 0 (0.0) 297.15 <0.0001
Community health center 7 (3.7) 123 (57.2)
Planned Parenthood 12 (6.3) 47 (21.9)
Private clinic 14 (7.4) 45 (20.9)
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Table 2. Comparison of HPV-Positive and HPV-Negative Women for HPV Vaccine Characteristics
HPV positive n¼ 190 HPV negative n¼ 215
Characteristic n (%) n (%) RRa (95% CI)
Heard about HPV
No 63 (33.2) 84 (39.1) 1.00 Referent
Yes 127 (66.8) 131 (60.9) 1.08 (0.87-1.35)
Heard about HPV vaccine
No 51 (27.0) 90 (42.1) 1.00 Referent
Yes 138 (73.0) 124 (57.9) 1.45 (1.09-1.93)
Missing 1 1
Concerns about HPV vaccine
None 134 (70.5) 166 (77.2) 1.00 Referent
Any 56 (29.5) 49 (22.8) 1.15 (0.92-1.43)
Side effects
Long-term side effects 22 (30.6) 33 (41.3)
Cost=covered by Medicaid 11 (15.3) 10 (12.5)
Short-term side effects 6 (8.3) 24 (30.0)
Safety 11 (15.3) 7 (9.7)
Effectiveness 14 (19.4) 3 (3.8)
Increase sexual activity 6 (8.3) 2 (2.5)
Age limit 2 (2.8) 1 (1.3)
Daughter vaccinated to prevent cervical cancer
No 1 (0.5) 9 (4.3) 1.00 Referent
Yes 187 (99.5) 203 (95.7) 5.14 (0.82-32.30)
Missing 2 3
Daughter vaccinated if pay yourself
No 1 (0.6) 11 (5.1) 1.00 Referent
Yes 182 (99.4) 203 (94.9) 5.86 (0.91-37.79)
Missing 7 1
Son vaccinated to prevent cervical cancer in partner
No 1 (0.5) 10 (4.9) 1.00 Referent
Yes 186 (99.5) 194 (95.1) 5.32 (0.89-31.95)
Missing 3 11
Texas law mandating HPV vaccine
Unsure=opposed 1.00 Referent
Unsure 6 (3.3) 17 (9.0)
Somewhat opposed 4 (2.2) 9 (4.2)
Strongly opposed 0 (0.0) 19 (8.0)
In favor 2.47 (1.36-4.48)
Strongly in favor 157 (85.3) 129 (60.9)
Somewhat in favor 17 (9.2) 38 (17.9)
Missing 6 3
Age to vaccinate girls against HPV
< 11 years 1.09 (0.82-1.45)
Infancy 11 (6.1) 24 (11.5)
5–10 years 25 (13.8) 16 (7.7)
11–12 years 77 (42.5) 68 (32.7) 1.00 Referent
>12 years 0.76 (0.60-0.97)
13–26 years 68 (37.6) 97 (46.6)
>26 years 0 (0.0) 3 (1.4)
Missing 9 7
Likely to get daughter vaccinatedb
Unsure=unlikely 1.00 Referent
Unsure 0 (0.0) 2 (3.4)
Somewhat unlikely 0 (0.0) 2 (3.4)
Very unlikely 0 (0.0) 2 (3.4)
Likely 2.02 (0.57-7.13)
Somewhat likely 6 (15.0) 17 (28.8)
Very likely 34 (85.0) 36 (61.0)
Missing 1 4
Know where to get vaccineb
No 7 (17.5) 35 (59.3) 1.00 Referent
Yes 33 (82.5) 24 (40.7) 2.93 (1.46-5.90)
Missing 1 4
(Continued)
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HPV vaccine for girls prior to entry into the sixth grade;
however, HPV-positive women were more than twice as
likely as HPV-negative women to be in favor of the law (RR
2.47, 95% CI 1.36-4.48). Fewer HPV-positive women than
HPV-negative women were in favor of vaccinating girls
against HPV at age >12 years (RR 0.76, 95% CI 0.60-0.97).
Among women with girls in the 9–18-year age range, which
qualifies them for the Vaccines for Children campaign, 85% of
HPV-positive women were very likely to have their daugh-
ters vaccinated compared with 61% of HPV-negative women.
Similarly, 83% of HPV-positive women with adolescent
daughters knew where to get the vaccine compared with 41%
of HPV-negative women (RR 2.93, 95% CI 1.46-5.90).
Discussion
Most Latinas living on the Texas-Mexico border find the
HPV vaccine acceptable for their daughters and sons, with
nearly all women indicating they would have their children
vaccinated against HPV. Finding high proportions of Latina
women reporting HPV vaccine acceptability for their children
is consistent with the existing literature. The HPV vaccine
acceptance for children in the current published literature
ranges from 68%12 to 100%,9 with several studies noting ac-
ceptance between 75% and 90%.13–16 In a Cuernavaca, Mex-
ico, study, Lazcano-Ponce et al.17 reported that 84% of women
would allow their daughters to participate in an HPV vaccine
trial. Constantine and Jerman18 conducted a telephone survey
representative of California and reported that Hispanic par-
ents were more likely than non-Hispanic parents to accept
vaccination of their daughters before age 13. In focus groups
conducted in Alabama, Scarinci et al.19 found that Latina
immigrants unanimously indicated they would get the vac-
cine for their daughters.
Our findings that more HPV-positive women had heard of
the HPV vaccine than had heard of HPV was somewhat
surprising; however, these percentages may have been similar
had we asked women about their awareness of the HPV
vaccine before we asked them about their awareness of HPV.
Both of these percentages were higher than the percentage of
HPV-negative women who reported they had heard of HPV
and the HPV vaccine; however, the difference was statistically
significant only for the HPV vaccine. During in-depth inter-
views we conducted with 45 HPV-positive women in 2004, a
lower percentage of women indicated they had heard of HPV
(53%) than either group of women in the current study.
Although rates of vaccine acceptability were high in this
study, we did find that HPV-positive women were more likely
to endorse vaccination for their children than were HPV-
negative women. Further, among women with adolescent
daughters, women with HPV were significantly more likely to
report that they were ‘‘very likely to get daughter vaccinated’’
compared with HPV-negative women and to know where
they could get the vaccine. This finding is consistent with
reports of greater vaccine acceptance in mothers who had a
history of genital warts7 or HPV infection8 or had experienced
cancer in the family.13 HPV-positive women may have higher
levels of perceived susceptibility and severity related to cer-
vical cancer (constructs from the Health Belief Model) than
HPV-negative women.20,21 Consistent with the Health Belief
Model, these beliefs would influence intention to vaccinate.
Fazekas et al.22 found that parents who believed the HPV
infection and cervical cancer were both likely and would have
negative consequences among their adolescent daughters
were more likely to report intending vaccination of an ado-
lescent daughter. This result is consistent with our finding
that HPV-positive women are more likely to understand the
risk and consequences of HPV infection and, therefore, to
intend to take preventive steps for their children.
We found no difference in parent’s acceptability of the HPV
vaccine for their children based on gender. This finding is
consistent with several small cross-sectional studies and one
qualitative study,8,10,11,23,24 yet a large intervention study
found parents more in favor of vaccinating their adolescent
daughters than their sons.7 HPV vaccine acceptability did not
differ by parent’s gender in the current study. We conducted
interviews with 62 men aged 18–64 years in the waiting rooms
of community health centers and private clinics from June
through November 2007. Over 90% of men reported they
would have their daughters and sons vaccinated against HPV
(data not shown).
The cost of the HPV vaccine has been noted as a barrier.25
Sauvageau et al.14 found that among respondents aged 25
years, 91% indicated they would receive the vaccine if it was
publicly funded, but only 72% indicated they would pay $100
per dose. In the current study, cost did not appear to be a
barrier, as nearly all HPV-positive woman and HPV-negative
women indicated they would get their daughter vaccinated
even if they had to pay for the series themselves. However,
just over 5% of all women indicated that cost or Medicaid
coverage was a concern for vaccination.
In the current study, women with HPV were significantly
more likely than women without HPV to strongly favor the
proposed Texas vaccine requirement. Although this law was
withdrawn because of both political and financial concerns,
the majority of women in this study favored the law. Because
Table 2. (Continued)
HPV positive n¼ 190 HPV negative n¼ 215
Characteristic n (%) n (%) RRa (95% CI)
Where
Clinic 9 (52.9) 8 (40.0)
Pediatrician 5 (29.4) 7 (35.0)
Private doctor 3 (17.7) 5 (25.0)
Missing 16 4
aRR, relative risk adjusted for age, marital status, and health insurance; CI, confidence interval.
bAmong women with daughters aged 9–18 years.
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HPV is an STI, there has been concern, especially among
racial=ethnic minorities, that encouragement of the HPV
vaccine during adolescence may encourage early sexual ac-
tivity.26 In the four studies that investigated this issue,8,10,18,24
however, a range of 6%–12% of parents worried that adoles-
cent HPV vaccination may promote early sexual activity. Our
finding that <5% of all women in our study were concerned
about increased sexual activity among vaccinated daughters
is similar to this range.
Our study had limitations. The differing response rates
between HPV-positive and HPV-negative women may have
introduced selection bias. The cross-sectional nature of the
study prevented the establishment of a temporal relation-
ship between HPV status and HPV acceptability. Because
only around two thirds of participants had heard of the HPV
vaccine, we had to provide a description, which may have
encouraged participants to respond affirmatively; however,
when we restricted the analysis to women who had heard of
HPV, our results were similar. We do not know if the women
had gotten the HPV vaccine themselves or had gotten the
vaccine for their daughters, which will be addressed in future
studies.
In addition, HPV-negative women were more likely to
have been interviewed sooner after approval of the vaccine
and from private clinics than HPV-positive women; however,
these variables did not confound the associations of interest.
We were unable to control for other potential confounders,
such as lifetime number of sexual partners, age at first inter-
course, and the sexual behavior of a woman’s partner. Be-
cause HPV infection is an STI HPV positivity can be viewed as
a proxy for the range of sexual behaviors of the woman and
her partner. These sexual behaviors may be associated with
vaccine acceptability and not necessarily with HPV positivity.
However, it is more likely that fear of cancer is the more im-
portant motivator for vaccine acceptance than sexual behav-
ior because, as we observed during in-depth interviews,
women with HPV identify more with their risk of cancer than
with having an STI.
Strengths of our study include the focus on an under-
studied population in which cervical cancer incidence and
mortality are quite high, the fairly large sample size that in-
creased the precision of estimates, and the assessment of
confounding by known correlates of HPV positivity. The HPV
vaccine, in combination with HPV prevention and cervical
cancer screening, presents an unprecedented opportunity to
drastically reduce cervical cancer incidence and mortality. The
risk of short-term increases in cervical cancer incidence and
mortality that may result from emphasizing HPV vaccine
receipt without emphasizing HPV prevention and cervical
cancer screening has been noted.27 In order to reduce the risk
of increases in cervical cancer incidence and mortality, addi-
tional studies should assess the impact of receipt of the HPV
vaccine on sexual practices and cervical cancer screening.
Conclusions
We found that HPV-negative women may be slightly less
interested in vaccinating their children than are HPV-positive
women. This finding may be explained by the woman’s per-
ceived lower risk of cervical cancer for herself and her children
relative to HPV-positive women. Educational efforts to in-
form all women of the benefits of HPV vaccination for their
daughters need to indicate clearly that (1) the vaccine protects
girls and women against both cervical cancer and genital
warts and (2) as with the other vaccination against an STI that
can cause cancer (hepatitis B), it is the child’s risk of HPV and
cancer that needs to be carefully considered. These educa-
tional efforts may lead to reductions in cervical cancer inci-
dence and mortality in high-risk populations, such as Latinas
living on the Texas-Mexico border.
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